Your browser version may not work well with NCBI's Web applications. More information here...
1: Inflamm Bowel Dis. 2004 May;10(3):258-60.Links

Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis.

Daniel F, Seksik P, Cacheux W, Jian R, Marteau P.

Département d'Hepato-Gastroentŕologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Derivatives of 5-aminosalicylic acid (5-ASA) used for the treatment of inflammatory bowel disease may induce acute pancreatitis of immunoallergic origin. 4-aminosalicylic acid (4-ASA) differs from its 5-ASA counterpart by the position of the NH2 group and has shown efficacy in ulcerative colitis. The risk of cross intolerance reaction between 5-ASA and 4-ASA has currently never been evaluated. We report three cases of 5-ASA-induced pancreatitis, with no recurrence of pancreatitis during subsequent treatment with 4-ASA enemas. We conclude that 4-ASA enemas are a safe and well-tolerated therapeutic alternative whenever 5-ASA-induced pancreatitis occurs.

PMID: 15290921 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Mesalamine (Asacol® , Canasa® , Pentasa® , ...)

    Mesalamine is used to treat ulcerative colitis (a condition in which part or all of the lining of the colon [large intestine] is swollen or worn away). Mesalamine delayed-release tablets and controlled-release capsules m...

  • Source: AHFS Consumer Medication Information